ICON Public’s (ICLR) “Equal Weight” Rating Reiterated at Barclays

Barclays restated their equal weight rating on shares of ICON Public (NASDAQ:ICLR) in a report issued on Thursday, Marketbeat.com reports. The brokerage currently has a $165.00 target price on the medical research company’s stock, down from their prior target price of $240.00.

A number of other equities research analysts have also recently issued reports on ICLR. Citigroup dropped their price target on shares of ICON Public from $290.00 to $215.00 and set a “buy” rating on the stock in a research note on Monday, April 7th. Truist Financial dropped their target price on shares of ICON Public from $262.00 to $208.00 and set a “buy” rating on the stock in a research report on Thursday. Robert W. Baird decreased their price target on shares of ICON Public from $221.00 to $203.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. Mizuho lowered their price objective on ICON Public from $238.00 to $200.00 and set an “outperform” rating on the stock in a report on Wednesday. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $263.00 target price on shares of ICON Public in a report on Wednesday, January 15th. Six equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $243.33.

ICON Public Trading Up 1.0 %

Shares of ICON Public stock opened at $144.04 on Thursday. The firm has a 50-day simple moving average of $179.62 and a two-hundred day simple moving average of $210.84. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.34 and a current ratio of 1.26. ICON Public has a fifty-two week low of $138.51 and a fifty-two week high of $347.72. The company has a market cap of $11.63 billion, a P/E ratio of 15.11, a price-to-earnings-growth ratio of 1.86 and a beta of 1.24.

ICON Public (NASDAQ:ICLR) last released its quarterly earnings results on Wednesday, February 19th. The medical research company reported $3.42 earnings per share for the quarter, topping analysts’ consensus estimates of $3.41 by $0.01. ICON Public had a return on equity of 11.81% and a net margin of 9.56%. The company had revenue of $2.04 billion during the quarter, compared to analysts’ expectations of $2.04 billion. As a group, equities analysts predict that ICON Public will post 13.38 earnings per share for the current fiscal year.

Institutional Trading of ICON Public

Large investors have recently added to or reduced their stakes in the stock. Sierra Ocean LLC purchased a new position in shares of ICON Public during the 4th quarter worth $29,000. Park Place Capital Corp increased its position in ICON Public by 281.4% during the fourth quarter. Park Place Capital Corp now owns 225 shares of the medical research company’s stock worth $47,000 after purchasing an additional 166 shares during the last quarter. Private Trust Co. NA raised its stake in ICON Public by 48.8% during the fourth quarter. Private Trust Co. NA now owns 250 shares of the medical research company’s stock worth $52,000 after purchasing an additional 82 shares during the period. NBC Securities Inc. acquired a new position in ICON Public in the 1st quarter valued at about $59,000. Finally, GAMMA Investing LLC grew its stake in shares of ICON Public by 64.0% in the 4th quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock valued at $91,000 after buying an additional 169 shares during the period. 95.61% of the stock is currently owned by hedge funds and other institutional investors.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.